Context Therapeutics presents CT-95 and CT-202 data at SITC Annual Meeting.
ByAinvest
Friday, Nov 7, 2025 7:33 am ET1min read
CNTX--
Context Therapeutics presented posters on CT-95 and CT-202 at the Society for Immunotherapy of Cancer's 40th Annual Meeting. CT-95, a mesothelin x CD3 bispecific TCE, is in a Phase 1 trial with 6 patients enrolled. Context is enrolling Cohort 3 with a priming dose of 0.18 µg/kg and a full dose of 0.6 µg/kg. CT-95 is projected to achieve target dose exposure starting at Cohort 4, and no CRS greater than Grade 2 has been observed.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet